Abstract
Immune thrombocytopenia (ITP) is a disease which sees one-third of patients failing first and subsequent therapeutic approaches, including splenectomy. Thrombopoietin-receptor agonists (TPO-RAs) are recommended for adults who relapse after splenectomy or who have contraindications for splenectomy. In this multicenter study, a total of 124 patients were retrospectively evaluated: 55 (44.3 %) were treated by romiplostim and 69 (55.6 %) by eltrombopag. Mean age, number of young patients (<60 years), time from primary diagnosis of ITP to TPO-RA treatment, and previous lines of therapy were similar in both groups. The overall response rate was 80 % (44/55) for romiplostim and 94.2 % (65/69) for eltrombopag; the duration of response and the time to response were similar (p = NS). The response rate to both drugs in non-splenectomized patients was higher than that of splenectomized patients (p < 0.05). The mean duration of response was 30 months for romiplostim and 15 months for eltrombopag, due to later commercialization of eltrombopag. Failure was the most frequent cause of discontinuation. Thrombotic events were the most consistent adverse events and were recorded in 2 and 3 % of patients treated by romiplostim and eltrombopag, respectively. In conclusion, romiplostim and eltrombopag are effective in the majority of patients with chronic ITP who failed several lines of therapy; whether TPO-RAs could substitute splenectomy is under discussion and studies are warranted.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Stasi R (2011) Pathophysiology and therapeutics options in primary immune thrombocytopenia. Blood Transfus 9:262–273
Neunert CE, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA (2011) The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 117:4190–4207
Neunert CE (2013) Individualized treatment for immune thrombocytopenia: predicting bleeding risk. Semin Hematol 50:S55–57
Rodeghiero, F., Stasi, R., Gernsheimer, T., Michel, M., Provan, D., Arnold, D.M., Bussel, J.B., Cines, D.B., Chong, B.H., Cooper, N., Godeau, B., Lechner, K., Mazzucconi, M.G., McMillan, R., Sanz, M.A., Imbach, P., Blanchette, V., Kühne, T., Ruggeri, M. & George, J.N.(2998) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood113(11):2386–93.
Choe MJ, Packer CD (2015) Severe romiplostim-induced rebound thrombocytopenia after splenectomy for refractory ITP. Ann Pharmacother 49:140–144
Cervinek, L., Majer, J.& Doubek, M. (2015) Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults. International Journal of Hematology, (Epub ahead print).
Mahevas M, Fain O, Ebbo M, Roudot-Thoraval F, Limal N, Khellaf M, Scleinitz N, Bierling P, Languille L, Godeau B, Michel M (2014) The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study. Br J Haematol 165:865–869
Bao W, Bussel JB, Heck S (2010) Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietin agents. Blood 116:4639–4645
Ghadaki B, Nazi I, Kelton JG, Arnold DM (2013) Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists. Transfusion 58:395–398
Kuter DJ, Bussel JB, Lyons RM (2010) Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomized controlled trial. Lancet 371:395–403
Kuter DJ, Rummel M, Boccia R (2010) Romiplostim or standard of care in patients with immune thrombocytopenic purpura. N Engl J Med 357:2237–2247
Polverelli N, Palandri F, Iacobucci I, Catani L, Martinelli G, Vianelli N (2013) Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic in chronic refractory immune thrombocytopenia: possible role of MPL polymorphisms. Br J Haematol 161:142–144
D’Arena G, Guariglia R, Mansueto G, Martorelli MC, Pietrantuono G, Villani O, Lerose R, Musto P (2013) No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura. Blood 121:1240–1242
Kashiwagi H, Tomiyama Y (2015) Recent advances in pathophysiology and treatment of immune thrombocytopenia. Rinsho Kesueki 56:177–184
Acknowledgments
The authors would like to thank Caroline Oakley for linguistic revision of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest. The authors received no financial support for the study.
Ethical standards
The study was conducted in accordance with the Declaration of Helsinki. All patients signed informed consent according to the regulations of each investigational site.
Rights and permissions
About this article
Cite this article
Mazza, P., Minoia, C., Melpignano, A. et al. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a “real life” retrospective multicenter experience of the Rete Ematologica Pugliese (REP). Ann Hematol 95, 239–244 (2016). https://doi.org/10.1007/s00277-015-2556-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-015-2556-z